Table 6 Selective clinical trials of immune checkpoint inhibitors
From: Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Drug | Target | Condition | Status | Phase | NCT identifier |
|---|---|---|---|---|---|
Ipilimumab | CTLA4 | mCRPC | Completed | 2 | NCT02279862 |
Ipilimumab | CTLA4 | mCRPC | Completed | 3 | NCT01057810 |
Ipilimumab | CTLA4 | mCRPC | Completed | 3 | NCT00861614 |
Atezolizumab | PD-L1 | mCRPC | Completed | 1 | NCT03024216 |
Atezolizumab | PD-L1 | mCRPC | Recruiting | 3 | NCT04446117 |
Durvalumab | PD-L1 | mCRPC | Completed | 2 | NCT03204812 |
Avelumab | PD-L1 | NEPC | Completed | 2 | NCT03179410 |
Pembrolizumab | PD1 | mCRPC | Recruiting | 1/2 | NCT02861573 |
Pembrolizumab | PD1 | mCRPC | Completed | 2 | NCT03473925 |
Pembrolizumab | PD1 | Hormone-sensitive PCa | Recruiting | 3 | NCT04934722 |
Pembrolizumab | PD1 | mCRPC | Recruiting | 3 | NCT03834493 |
Pembrolizumab | PD1 | mCRPC | Recruiting | 3 | NCT04907227 |
Nivolumab | PD1 | mCRPC | Completed | 2 | NCT02601014 |
Nivolumab | PD1 | mCRPC | Recruiting | 3 | NCT04100018 |
Ipilimumab + Nivolumab | CTLA4, PD1 | mCRPC with CDK12 mutations | Recruiting | 2 | NCT03570619 |
